


Pin Therapeutics implements CDD Vault to facilitate collaborative research in Targeted Protein Degradation

SEOUL, SOUTH KOREA, January 30, 2023 /EINPresswire.com/ -- Pin Therapeutics, a biotech company focused on developing new therapies in the field of E3 ligase and Molecular Glue Degraders, announced today that it has migrated all its R&D data to CDD Vault, an informatics platform developed by Collaborative Drug Discovery, to support its quest for nextgeneration diagnostics and cures. With research teams located in Korea and USA, Pin needed a data management system to support its distributed workforce and innovative research while improving R&D productivity. CDD Vault was selected following an exhaustive evaluation, and within a few weeks all data was migrated. Scientists are now working productively in the new platform.

Pin focuses on Targeted Protein
Degradation (TPD) technology and is
developing two types of drugs: PROTAC
(PROteolysis-TArgeting Chimera) and
Molecular Glue Degrader. Through a
logically designed library and screening
technique, Pin is developing new
molecular glue degraders and platform
technologies that can efficiently



CDD, VAULT®

Complexity Simplified

identify and selectively degrade target proteins. In fact, Pin has established a platform technology to rapidly and efficiently identify novel and optimized binders that bind to E3 Ligase

targets.

"We were working with another software before, but found that CDD Vault is easier and more flexible to use. We now use CDD Vault to store and mine all small molecules and assay information as it is proven to be the ideal tool for sharing information across teams. In addition, CDD's support team has been very responsive in supporting us through the migration process."

About Pin Therapeutics, Inc.

Pin Therapeutics (<u>www.pintherapeutics.com</u>, "Pin") is a biotech company in Targeted Protein Degradation (TPD) field and located in South Korea and SF. With the experts in various parts of new drug discovery, Pin is developing novel platforms and screening systems called "PinE3" (for novel E3 ligases) and "PinGLUE" (for novel Molecular Glue Degraders) to address the limitations of current TPD technology, and develop promising pipelines targeting specific medical unmet needs in the field.

About Collaborative Drug Discovery, Inc.

CDD's (www.collaborativedrug.com) flagship product, "CDD Vault®", is used to manage chemical registration, structure-activity relationships (SAR), and securely scale collaborations. CDD Vault® is a hosted database solution for secure management and sharing of biological and chemical data. It lets you intuitively organize chemical structures and biological study data, and collaborate with internal or external partners through an easy to use web interface. Available modules within CDD Vault include Activity & Registration, Visualization, Inventory, and ELN.

Abraham Wang Collaborative Drug Discovery email us here

This press release can be viewed online at: https://www.einpresswire.com/article/613739458

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.